{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:11:12Z","timestamp":1778908272547,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.exphem.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T17:00:37Z","timestamp":1674666037000},"page":"14-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing"],"prefix":"10.1016","volume":"119-120","author":[{"given":"Oriane","family":"C\u00e9dile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3083-4850","authenticated-orcid":false,"given":"Marcus H\u00f8y","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-4276","authenticated-orcid":false,"given":"Sara Kamuk","family":"Dahlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas Kielsgaard","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-7594","authenticated-orcid":false,"given":"Charlotte Guldborg","family":"Nyvold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2023.01.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.exphem.2023.01.002_bib0002","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3389\/fimmu.2019.01121","article-title":"Cell of origin and genetic alterations in the pathogenesis of multiple myeloma","volume":"10","author":"Barwick","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0003","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"1","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0004","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.exphem.2023.01.002_bib0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0006","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0007","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.exphem.2023.01.002_bib0008","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.01.002_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237155","article-title":"The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements","volume":"15","author":"Cedena","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2023.01.002_bib0010","doi-asserted-by":"crossref","first-page":"862","DOI":"10.5858\/arpa.2021-0088-OA","article-title":"Interlaboratory analytical validation of a next-generation sequencing strategy for clonotypic assessment and minimal residual disease monitoring in multiple myeloma","volume":"146","author":"Medina","year":"2022","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.exphem.2023.01.002_bib0011","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/hemato3030031","article-title":"Minimal residual disease in multiple myeloma\u2014current approaches and future clinical implications","volume":"3","author":"Akhlaghi","year":"2022","journal-title":"Hemato"},{"key":"10.1016\/j.exphem.2023.01.002_bib0012","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/sj.leu.2404479","article-title":"Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936","volume":"21","author":"Evans","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.002_bib0013","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2012.246","article-title":"EuroClonality\/BIOMED-2 guidelines for interpretation and reporting of Ig\/TCR clonality testing in suspected lymphoproliferations","volume":"26","author":"Langerak","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.002_bib0014","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-62703-269-8_4","article-title":"PCR-based analysis of rearranged immunoglobulin or T-cell receptor genes by GeneScan analysis or heteroduplex analysis for clonality assessment in lymphoma diagnostics","volume":"971","author":"Boone","year":"2013","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0015","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma","volume":"31","author":"Martinez-Lopez","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.002_bib0016","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","article-title":"Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study","volume":"33","author":"Bruggemann","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.002_bib0017","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jmoldx.2018.10.008","article-title":"Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms","volume":"21","author":"Arcila","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.exphem.2023.01.002_bib0018","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fonc.2019.00449","article-title":"Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma","volume":"9","author":"Yao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0019","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jmoldx.2020.02.005","article-title":"Upgraded standardized minimal residual disease detection by next-generation sequencing in multiple myeloma","volume":"22","author":"Yao","year":"2020","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.exphem.2023.01.002_bib0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/genes12070979","article-title":"Immune gene rearrangements: unique signatures for tracing physiological lymphocytes and leukemic cells","volume":"12","author":"Kotrova","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.exphem.2023.01.002_bib0021","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.01.002_bib0022","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.01.002_bib0023","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation","volume":"28","author":"Takamatsu","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0024","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.exphem.2021.03.005","article-title":"Perspective: sensitive detection of residual lymphoproliferative disease by NGS and clonal rearrangements-how low can you go?","volume":"98","author":"Hansen","year":"2021","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0026","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2023.01.002_bib0027","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jmoldx.2020.10.015","article-title":"Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high-sensitivity flow cytometry","volume":"23","author":"Ho","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.exphem.2023.01.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101149","article-title":"Monitoring minimal residual disease in the bone marrow using next generation sequencing","volume":"33","author":"Rustad","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0029","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.archoralbio.2018.08.020","article-title":"Differential cellular composition of human palatine and pharyngeal tonsils","volume":"96","author":"Stanisce","year":"2018","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.exphem.2023.01.002_bib0030","doi-asserted-by":"crossref","first-page":"11077","DOI":"10.1038\/s41598-017-09689-x","article-title":"Characterization of tonsillar IL10 secreting B cells and their role in the pathophysiology of tonsillar hypertrophy","volume":"7","author":"Sarmiento Varon","year":"2017","journal-title":"Sci Rep"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2300022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2300022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:38:11Z","timestamp":1759567091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X2300022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":29,"alternative-id":["S0301472X2300022X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2023.01.002","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}